Home > News > Nanogen Announces Type II Diabetes Research Collaboration
May 15th, 2006
Nanogen Announces Type II Diabetes Research Collaboration
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, has announced a collaboration agreement with Oy Jurilab, Ltd., the Finnish genomics company. The collaboration is designed to identify and validate new prognostic markers for type II diabetes, one of the leading causes of death in the United States.
Source:
prnewswire
Bookmark:
| Related News Press |
Nanomedicine
Fighting cancer with sticky nanoparticles September 27th, 2016
Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016
Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016
BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016
Announcements
Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016
Fighting cancer with sticky nanoparticles September 27th, 2016
Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016
UNAM develops successful nano edible coating which increases life food September 27th, 2016
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||
